<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/193946</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;193946v2</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;193946</article-id><article-id pub-id-type="other" hwp:sub-type="slug">193946</article-id><article-id pub-id-type="other" hwp:sub-type="atom-slug">193946</article-id><article-id pub-id-type="other" hwp:sub-type="tag">193946</article-id><article-version>1.2</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Microbiology" hwp:journal="biorxiv"><subject>Microbiology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1"><label>§</label>Corresponding Author: Adam M. Spivak, 50 North Medical Drive, Division of Infectious Diseases, Room 4B319, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, Phone: 801-587-1964, Fax: 801-585-3377, <email hwp:id="email-1">adam.spivak@hsc.utah.edu</email></corresp><fn id="n1" fn-type="equal" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1 xref-fn-1-2"><label>*</label><p hwp:id="p-1">Contributed equally</p></fn><fn fn-type="others" hwp:id="fn-2"><p hwp:id="p-2">ETL <email hwp:id="email-2">erin.larragoite@path.utah.edu</email></p><p hwp:id="p-3">RAN <email hwp:id="email-3">racheal.nell@outlook.com</email></p><p hwp:id="p-4">LJM <email hwp:id="email-4">laura.martins@path.utah.edu</email></p><p hwp:id="p-5">LRB <email hwp:id="email-5">lbarrows@pharm.utah.edu</email></p><p hwp:id="p-6">VP <email hwp:id="email-6">vicente.planelles@path.utah.edu</email></p><p hwp:id="p-7">AMS <email hwp:id="email-7">adam.spivak@hsc.utah.edu</email></p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Larragoite Erin T."><surname>Larragoite</surname><given-names>Erin T.</given-names></name><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">*</xref><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Nell Racheal A."><surname>Nell</surname><given-names>Racheal A.</given-names></name><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-2" hwp:rel-id="fn-1">*</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Martins Laura J."><surname>Martins</surname><given-names>Laura J.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Barrows Louis R."><surname>Barrows</surname><given-names>Louis R.</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Planelles Vicente"><surname>Planelles</surname><given-names>Vicente</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Spivak Adam M."><surname>Spivak</surname><given-names>Adam M.</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">§</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3"><label>1</label><institution hwp:id="institution-1">Department of Pathology, University of Utah</institution>, Salt Lake City, <country>United States</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2"><label>2</label><institution hwp:id="institution-2">Department of Medicine, University of Utah School of Medicine</institution>, Salt Lake City, <country>United States</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1"><label>3</label><institution hwp:id="institution-3">Department of Pharmacology and Toxicology, University of Utah</institution>, Salt Lake City, <country>United States</country></aff></contrib-group><pub-date pub-type="epub-original" date-type="pub" publication-format="electronic" hwp:start="2021"><year>2021</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2017-09-27T05:31:32-07:00">
    <day>27</day><month>9</month><year>2017</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2021-09-08T08:21:31-07:00">
    <day>8</day><month>9</month><year>2021</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2017-09-27T05:36:59-07:00">
    <day>27</day><month>9</month><year>2017</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2021-09-08T08:28:16-07:00">
    <day>8</day><month>9</month><year>2021</year>
  </pub-date><elocation-id>193946</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2017-09-26"><day>26</day><month>9</month><year>2017</year></date>
<date date-type="rev-recd" hwp:start="2021-09-07"><day>07</day><month>9</month><year>2021</year></date>
<date date-type="accepted" hwp:start="2021-09-08"><day>08</day><month>9</month><year>2021</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2021</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-8">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="193946.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/change-list" xlink:role="change-list" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2021/pdf/193946v2.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="193946.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2021/abstracts/193946v2/193946v2.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2021/fulltext/193946v2/193946v2.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><sec hwp:id="sec-1"><title hwp:id="title-2">Introduction</title><p hwp:id="p-9">Latency reversal agents (LRAs), such as protein kinase C (PKC) agonists, constitute a promising strategy for exposing and eliminating the HIV-1 latent reservoir. PKC agonists activate NF-κB and, in turn, induce deleterious pro-inflammatory cytokine production. Adjuvant pharmacological agents, such as ruxolitinib, a JAK inhibitor, and rapamycin, an mTOR inhibitor, have previously been combined with LRAs to reduce deleterious pro-inflammatory cytokine secretion without inhibiting HIV-1 viral reactivation in vitro. Histone deacetylase inhibitors (HDACi) are known to dampen pro-inflammatory cytokine secretion in the context of other diseases and can synergize with other LRAs to bring dormant proviruses out of latency. In this study we investigated whether a broad panel of epigenetic modifiers, including HDACi, could effectively dampen PKC-induced pro-inflammatory cytokine secretion during latency reversal.</p></sec><sec hwp:id="sec-2"><title hwp:id="title-3">Methods</title><p hwp:id="p-10">We screened an epigenetic modifier library to identify compounds that reduced intracellular IL-6 production induced by the PKC agonist Ingenol-3,20-dibenzoate. We further tested the most promising epigenetic inhibitor class, histone deacetylase inhibitors, for their ability to reduce a broad panel of pro-inflammatory cytokines <italic toggle="yes">ex vivo</italic>.</p></sec><sec hwp:id="sec-3"><title hwp:id="title-4">Results</title><p hwp:id="p-11">We identified nine epigenetic modulators that reduced PKC-induced intracellular IL-6. In cells from aviremic individuals living with HIV-1, the HDAC1-3 inhibitor, suberohydroxamic acid (SBHA), reduced secretion of pro-inflammatory cytokines TNF-α, IL-5, and IL-17 when used in combination with Ingenol-3,20-dibenzoate.</p></sec><sec hwp:id="sec-4"><title hwp:id="title-5">Conclusion</title><p hwp:id="p-12">The addition of SBHA to Ingenol-3,20-dibenzoate reduces deleterious cytokine production during latency reversal in aviremic donor PBMCs. The ability of SBHA to reduce PKC-induced pro-inflammatory cytokines when used in combination with Ingenol-3,20-dibenzoate makes the combination an attractive latency reversal therapy.</p></sec></abstract><kwd-group kwd-group-type="author" hwp:id="kwd-group-1"><title hwp:id="title-6">Keywords</title><kwd hwp:id="kwd-1">HIV-1</kwd><kwd hwp:id="kwd-2">Latency Reversing Agent</kwd><kwd hwp:id="kwd-3">Ingenol-3</kwd><kwd hwp:id="kwd-4">20-dibenzoate</kwd><kwd hwp:id="kwd-5">suberohydroxamic acid</kwd><kwd hwp:id="kwd-6">cytokine</kwd><kwd hwp:id="kwd-7">HDACi</kwd></kwd-group><counts><page-count count="25"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta><notes hwp:id="notes-1"><notes notes-type="competing-interest-statement" hwp:id="notes-2"><title hwp:id="title-7">Competing Interest Statement</title><p hwp:id="p-13">The authors have declared no competing interest.</p></notes><fn-group content-type="summary-of-updates" hwp:id="fn-group-1"><title hwp:id="title-8">Summary of Updates:</title><fn fn-type="update" hwp:id="fn-3"><p hwp:id="p-14">Here, we have further examined the ability of epigenetic modifiers to reduce PKC induced pro-inflammatory cytokines. We show that histone deacetylase (HDAC) inhibitors reduce ingenol-3,20-dibenzoate induced pro-inflammatory cytokines and identify suberohydroxamic acid (SBHA) as a reducer of PKC induced pro-inflammatory cytokines TNF-a, IL-5, and IL-17.</p></fn></fn-group></notes></front><body><sec id="s1" hwp:id="sec-5"><label>1.</label><title hwp:id="title-9">Introduction</title><p hwp:id="p-15">Antiretroviral therapy (ART) has improved the lives of individuals living with HIV-1 by durably blocking viral replication, reducing plasma viremia levels below the limit of detection (∼20-50 copies/ml) [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>-<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>], and allowing for reconstitution of the adaptive immune system. However, ART does not result in HIV-1 eradication due to the presence of a transcriptionally silent, long-lived latent viral reservoir [<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref>-<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>]. The presence of this latent reservoir makes ART a lifelong necessity [<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>]. Additionally, not all patients have access to ART or are compliant with ART regimens due to high costs [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>], side effects [<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>], and social stigma [<xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>, <xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>]. Aviremic individuals taking ART are prone to low-level chronic immune activation and exhaustion [<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>], cardiovascular disease [<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>, <xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>], non-AIDS related cancers [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>], and neurologic complications [<xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>], underscoring the importance of strategies targeting the latent HIV-1 reservoir.</p><p hwp:id="p-16">The “shock and kill” strategy [<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>] proposes that a latency reversing agent (LRA) be used to transcriptionally reactivate the latent reservoir followed by targeting infected cells with immune-mediated mechanisms [<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-2" hwp:rel-id="ref-17">17</xref>, <xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>]. Immunological strategies include the use of broadly neutralizing antibodies (bNAbs), cytokines, vaccines, chimeric antigen receptors, and other immune-mediated mechanisms to enhance recognition of HIV-1 infected cells [<xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>, <xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>]. While all strategies hold merit, enhanced targeting of latently infected cells via immune-mediated mechanisms would still be dependent on unmasking the latent reservoir.</p><p hwp:id="p-17">Several mechanistic classes have emerged as potential LRAs including positive transcription elongation factor b (PTEFb) activators [<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>, <xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>], cytokines [<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>], histone deacetylase inhibitors (HDACi) [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>-<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref>], and protein kinase C (PKC) agonists [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-2" hwp:rel-id="ref-18">18</xref>, <xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-2" hwp:rel-id="ref-28">28</xref>-<xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>]. Spina <italic toggle="yes">et al</italic>. [<xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>] demonstrated that PKC agonists are uniquely efficacious LRAs across multiple in vitro models of HIV-1 latency, whereas other well characterized LRAs such as HDACi had functionality only in select in vitro models. PKC agonists are thought to reactivate latent HIV-1 though activation of NF-κB and have been shown to additionally activate AP-1 and NFAT [<xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref>]. On the other hand, PKC agonists have undesired effects, including induction of T cell activation [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>] and pro-inflammatory cytokine secretion. We previously demonstrated that latency reversal with the PKC agonist Ingenol-3,20-dibenzoate, used in combination with a second pharmacological agent, ruxolitinib (an FDA approved Janus Kinase [JAK] inhibitor), led to potent reactivation of latent HIV-1 in the absence of pro-inflammatory cytokine secretion[<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref>]. Additionally, rapamycin, an inhibitor of mTOR, has been shown to reduce pro-inflammatory cytokine secretion induced upon reactivation of latent HIV-1 with CD3 and CD28 antibodies [<xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>]. These studies indicate that latency reversal and pro-inflammatory cytokine secretion can be uncoupled. In the present study we expanded our search for epigenetic modifiers that could be used as an adjuvant therapy to reduce cytokine secretion induced by PKC agonists.</p><p hwp:id="p-18">While ruxolitinib and rapamycin have been shown to reduce in vivo cytokine secretion in the context of HIV-1, HDACi have also been observed to inhibit pro-inflammatory cytokine secretion in vivo in the context of graft-versus-host disease [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>] and rheumatoid arthritis [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>] as well as in vitro, in the context of LPS stimulation of human peripheral blood mononuclear cells (PBMCs) [<xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>]. Additionally, HDACi are well-known HIV LRAs and it has been shown that they can have additive or synergistic activity with PKC agonists when reactivating latent HIV-1 [<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref>, <xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>, <xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref>]. Therefore, we hypothesized that HDACi and potentially other epigenetic modifiers could decrease PKC-induced pro-inflammatory cytokines secretion and be used as a combination therapy with PKC agonists during latency reversal. In this study, we performed a screen of epigenetic modifiers and report that suberohydroxamic acid (SBHA), an HDAC1- and 3-inhibitor, suppresses PKC-induced pro-inflammatory cytokines.</p></sec><sec id="s2" hwp:id="sec-6"><label>2.</label><title hwp:id="title-10">Materials and Methods</title><sec id="s2a" hwp:id="sec-7"><title hwp:id="title-11">Participants</title><p hwp:id="p-19">Participants living with and without HIV-1 infection were recruited in accordance with active University of Utah Institutional Review Board (IRB) protocols 58246 and 67637 respectively. Participants living with HIV-1 infection were aviremic (plasma viral loads less than 50 HIV-1 RNA copies/mL) for a minimum of 6 months and prescribed an ART regimen initiated during chronic HIV-1 infection for a minimum of 12 months.</p></sec><sec id="s2b" hwp:id="sec-8"><title hwp:id="title-12">In vitro epigenetic inhibitor screening</title><p hwp:id="p-20">PBMCs were isolated from healthy donors using a Lymphoprep density gradient (Cat# 07861, StemCell Technologies) prior to being cultured in RPMI medium supplemented with 10% FBS and 5 U/mL penicillin/streptomycin overnight to remove monocytes via adherence. Non-adherent PBMCs were then cultured at a density of 1 × 10<sup>5</sup> cells/100µL in the presence of 100nM compounds from a Cayman Chemical Epigenetics Screening Library obtained from the University of Utah Drug Discovery Core Facility (Item No. 11076) or 100nM ruxolitinib (Cayman Chemical Co., Item No. 11609), a control for cytokine inhibition, for 1.5 h at 37°C. Cells were then incubated in medium alone or the presence of 100nM IDB for 40 hours post-stimulant exposure. At 40 hours post-stimulant exposure, 0.067 µL/100µL BD GolgiStop™ Protein Transport Inhibitor (Cat# 554724) was added to each sample to inhibit cytokine secretion. Cells were then fixed and stained at 48 hours prior to flow cytometry analysis.</p></sec><sec id="s2c" hwp:id="sec-9"><title hwp:id="title-13">Intracellular cytokine staining and flow cytometry</title><p hwp:id="p-21">Cells were washed with 1x phosphate buffered saline (PBS) prior to staining the cells with 0.1µL/100 µL Fixable Viability Dye eFluor® 450 (Cat# 65-0863-14, Affymetrix eBioscience) for 30 min at 4°C. Cells were then washed with 1x PBS prior to fixing with 100 µL BD Cytofix/Cytoperm™ for 30 min at 4°C. Once cells were fixed, they were washed with a perm/wash solution (1x PBS, 3% FBS, 0.1% Saponin, 0.05% Sodium Azide) prior to staining cells in 100 µL perm/wash with 0.5 µL APC anti-human IL-6 antibody (Cat# 501112, Biolegend®) overnight at 4°C. Cells were finally washed in 1x PBS and re-suspended in PBS prior to flow cytometry [BD FACSCanto™ flow cytometer with FACSDiva™ acquisition software (Becton-Dickinson, Mountain View, CA)] and analysis with FlowJo (TreeStar Inc, Ashland, OR).</p></sec><sec id="s2d" hwp:id="sec-10"><title hwp:id="title-14">Selection of compounds</title><p hwp:id="p-22">The percentage of IL-6-positive cells in Ingenol-3,20-dibenzoate-alone-treated cells was compared to cells treated with epigenetic modifiers and IDB in order to calculate intracellular IL-6 fold-change. The top epigenetic modifiers that reduced intracellular IL-6 by four-fold or greater (‘hits’) were selected for testing in aviremic patient cells to determine whether these compounds would diminish PKC induced pro-inflammatory cytokines.</p></sec><sec id="s2e" hwp:id="sec-11"><title hwp:id="title-15">Ex vivo cell culture, qPCR, and cytokine measurements</title><p hwp:id="p-23">PBMCs were isolated from donors living with HIV-1 infection prior to the isolation of resting CD4<sup>+</sup> T cells (rCD4s) (EasySep™ Human Resting CD4<sup>+</sup> T Cell Isolation Kit, Cat # 17962, StemCell Technologies). rCD4s were cultured at a density of 5 × 10<sup>6</sup>/mL in RPMI supplemented with 10% FBS and 5U/mL penicillin/streptomycin. Epigenetic modifiers (Chidamide, Apicidin, Entinostat, Suberohydroxamic Acid (SBHA), Pyroxamide, Panobinostat, WDR5-0103, Iniparib and CCG-100602) that reduced intracellular IL-6 were added at 50nM to rCD4s in the presence of medium or IDB (45nM) for 48 hours. Medium or DMSO and Dynabead™ Human T-Activator αCD3/αCD28 (αCD3/ αCD28) (Cat# 11132D, Gibco™) stimulated cells were used as controls. At 48 hours post-stimulation, supernatant was collected and the <underline>r</underline>apid <underline>e</underline>x <underline>v</underline>ivo <underline>e</underline>valuation of <underline>a</underline>nti-latency assay (REVEAL) assay was performed as previously described [<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-3" hwp:rel-id="ref-28">28</xref>] to quantify viral release. Additionally, PBMCs from HIV-1 positive aviremic donors were cultured at a density of 3 × 10<sup>6</sup>/ml in RPMI supplemented with 10% FBS and 5U/mL penicillin/streptomycin. The epigenetic modifiers that induced the highest level of reactivation when combined with IDB (SBHA, Panobinostat, and Pyroxamide) were added at 75nM or 100nM concentrations in the presence of medium or IDB for 48 hours. Cells cultered in medium alone were used as controls. Supernatant was collected and sent to ARUP Laboratories to measure ex vivo cytokine secretion via a commercially available quantitative multiplex bead assay to measure the following cytokines: interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL) 1 beta (IL-1β), IL-2, soluble IL-2 receptor (IL-2r), IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, and IL-13.</p></sec><sec id="s2f" hwp:id="sec-12"><title hwp:id="title-16">Statistical Analysis</title><p hwp:id="p-24">Significant changes in reactivation or the secretion of pro-inflammatory cytokines in cells treated with epigenetic modifiers in combination with IDB compared to IDB alone was calculated with GraphPad Prism Version 5.0f (GraphPad Software, Inc., San Diego CA). Statistical significance was calculated using a non-parametric Wilcoxon matched-pairs signed rank test.</p></sec></sec><sec id="s3" hwp:id="sec-13"><label>3.</label><title hwp:id="title-17">Results</title><p hwp:id="p-25">HDACi have been previously described to inhibit cytokine secretion [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-2" hwp:rel-id="ref-35">35</xref>-<xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-2" hwp:rel-id="ref-37">37</xref>]. Therefore, we investigated the ability of HDACi and other epigenetic modifiers to reduce pro-inflammatory cytokine secretion upon latency reversal with a PKC agonist. We conducted a screen of 96 epigenetic modifiers (Cayman Chemical Co.) in primary CD4<sup>+</sup> T cells to identify those that more efficiently quelled the induction of pro-inflammatory cytokines during latency reversal with ingenol-3,20-dibenzoate (IDB). We used IL-6 as a prototypical cytokine for the screen. Nine epigenetic modifiers were identified which reduced intracellular IL-6 levels by four-fold or greater in the context of IDB stimulation (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1</xref></bold>). These ‘hits’ include six HDACi (Chemical Abstracts Service (CAS) # 743420-02-2 (chidamide), CAS # 183506-66-3 (apicidin), CAS # 209783-80-2 (entinostat), CAS # 38937-66-5 (suberohydroxamic acid (SBHA)), CAS # 382180-17-8 (pyroxamide), CAS # 404950-80-7 (panobinostat)), one mixed lineage leukemia (MLL) inhibitor Cas # 890190-22-4 (WDR5-0103), and two compounds categorized as ‘miscellaneous’ as they did not have the same function as other epigenetic modifiers in the library. Out of the two compounds categorized as miscellaneous, compound Cas # 160003-66-7 (Iniparib), has an unknown function and compound Cas # 1207113-88-9 (CCG-100602) is an inhibitor of Rho pathway-mediated signaling [<xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref>]. The positive control, ruxolitinib, also reduced intracellular IL-6 by greater than fourfold as previously shown [<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-2" hwp:rel-id="ref-33">33</xref>]. As HDACi accounted for six out of nine ‘hits’, HDACi were selected for further validation ex vivo on cells from aviremic individuals living with HIV. The top three HDACi SBHA, Panobinostat, and Pyroxamide were determined to be the most promising epigenetic modifiers to reduce pro-inflammatory cytokine production in the context of IDB stimulation. We examined SBHA and Panobinostat for their ability to reduce secretion of a broad panel of pro-inflammatory cytokines ex vivo (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2</xref></bold>).</p><fig id="fig1" position="float" fig-type="figure" orientation="portrait" hwp:id="F1" hwp:rev-id="xref-fig-1-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;193946v2/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1.</label><caption hwp:id="caption-1"><title hwp:id="title-18">Epigenetic modifiers screening identifying compounds that dampen cytokine production induced by Ingenol-3,20-dibenzoate.</title><p hwp:id="p-26">Screening of 96 epigenetic modifiers for compounds that reduced intracellular IL-6 induced by IDB in healthy donor PBMCs (n=1) revealed nine epigenetic modifier ‘hits’ that reduce intracellular IL-6 by fourfold or greater (at or below dotted line) when compared to IDB treatment alone. Ruxolitinib was included as a positive control for reduction of intracellular IL-6 when combined with Ingenol-3,20-dibenzoate. Compounds are listed by CAS number and color coded according to categorized function. All nine ‘hits’ were selected for further testing.</p></caption><graphic xlink:href="193946v2_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><fig id="fig2" position="float" fig-type="figure" orientation="portrait" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;193946v2/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2.</label><caption hwp:id="caption-2"><title hwp:id="title-19">A) SBHA reduces pro-inflammatory cytokine secretion induced by IDB ex vivo.</title><p hwp:id="p-27">Solid lines represent the mean change in pro-inflammatory cytokine concentrations in the supernatant of PBMCs isolated from HIV-1 positive aviremic individuals (n = 8) and treated with SBHA (75nM or 100nM) and IDB (100nM) for 72 hours compared to IDB alone. The dotted line represents the baseline for the assay. <sup>*</sup>P value &lt;0.05; <sup>**</sup>P value &lt;0.01. 2<bold>B)</bold> Panobinostat has no significant effect on IDB induced pro-inflammatory cytokine production ex vivo. PBMCs from aviremic individual was treated with Panobinostat (100nM) and IDB (100nM). The mean change in pro-inflammatory cytokines is indicated by a solid line and dotted lines indicate the baseline for the assay.</p></caption><graphic xlink:href="193946v2_fig2A" position="float" orientation="portrait" hwp:id="graphic-2"/><graphic xlink:href="193946v2_fig2B" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-28">Treatment of aviremic patient PBMCs with IDB significantly increased TNF-α (p = 0.0156), IFN-γ (p = 0.0312), IL-1β (p =0.0156), IL-5 (p = 0.0156), IL-8 (p = 0.0156), IL-13 (p = 0.0156), and IL-17 (p = 0.0156) (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2A</xref></bold>). The addition of 75nM or 100nM SBHA to 100nM IDB was found to significantly reduce secreted levels of TNF-α (p = 0.0078), IL-5 (p = 0.0156), IL-2r (p = 0.0078), and IL-17 (p = 0.0156) (n = 8) (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2A</xref></bold>) ex vivo. For IL-13 statistical significance was not achieved (p = 0.0547) upon treatment of cells with IDB and 75nM SBHA. However, the addition of SBHA to IDB stimulation did not diminish the induction of IFN-γ and IL-8, which are significantly induced by IDB treatment. The effect of SBHA on IDB -induced IL-6 and IL-1β levels appeared inconsistent between donors ex vivo, with donors clustered into two distinct populations. Three donors (H027, H052, and H058) appeared to cluster above the mean pg/mL IL-6 when donor PBMCs were treated with Ingenol-3,30-dibenzoate and SBHA at 75nM or 100nM. In the remaining 5 donors (H037, H055, H063, H065 and H068), IL-6 appeared to decrease to near the limit of detection, though this decrease was not statistically significant when treated with either 75nM (p =0.0625) or 100nM (p = 0.1250) SBHA. Secreted IL-2, IL-4, IL-10, and IL-12 levels remaining unchanged upon treatment with IDB and the combination therapy. The addition of 100nM panobinostat to 100nM IDB did not significantly reduce secreted levels of any cytokines measured (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 2B</xref></bold>; TNF-α (p = 0.2500), IFN-γ (p = 0.5000), IL-1β (p = 0.2500), IL-2 (p &gt; 0.9999), IL-2r (p = 0.2500), IL-4 (p &gt; 0.9999), IL-5 (p = 0.5000), IL-6 (0.5000), IL-8 (p &gt; 0.9999), IL-10 (0.5000), IL-12 (no difference), IL-13 (p = 0.2500)) (Figure 3B). Secreted IL-17 was not measured.</p></sec><sec id="s4" hwp:id="sec-14"><label>4.</label><title hwp:id="title-20">Discussion</title><p hwp:id="p-29">In order to eliminate the latent HIV-1 reservoir, LRA therapies must be evaluated based on both their potency and deleterious side effects. PKC agonists are among the most potent LRAs that have emerged across multiple models of HIV-1 latency [<xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-2" hwp:rel-id="ref-29">29</xref>, <xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-2" hwp:rel-id="ref-30">30</xref>]. However, PKC agonists are also known to induce T cell activation [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-2" hwp:rel-id="ref-32">32</xref>] and secretion of pro-inflammatory cytokines [<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-3" hwp:rel-id="ref-33">33</xref>, <xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref>]. Previous reports have demonstrated that LRAs can be combined with a second pharmacological agent to suppress deleterious pro-inflammatory cytokine secretion induced upon treatment with PKC agonists [<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-4" hwp:rel-id="ref-33">33</xref>] and TCR stimulation [<xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-2" hwp:rel-id="ref-34">34</xref>]. While HDAC inhibitors such as SAHA [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-3" hwp:rel-id="ref-35">35</xref>, <xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-3" hwp:rel-id="ref-37">37</xref>], Trichostatin A [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-2" hwp:rel-id="ref-36">36</xref>], and Nicotinamide [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-3" hwp:rel-id="ref-36">36</xref>] have been shown to reduce pro-inflammatory cytokine secretion in other disease contexts [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-4" hwp:rel-id="ref-35">35</xref>, <xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-4" hwp:rel-id="ref-36">36</xref>], we here for the first time have examined the ability of these compounds to do so.</p><p hwp:id="p-30">HDAC1-3 inhibition is a known mechanism of inhibiting the production of pro-inflammatory cytokines [<xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>-<xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>]. HDAC1- and HDAC3-independent knock-down have been previously shown to reduced LPS-induced IL-6 and TNF-α in murine microglia [<xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-2" hwp:rel-id="ref-42">42</xref>] and IL-1 pro-inflammatory cytokine induction in HEK293IL-1R and mouse embryonic fibroblasts [<xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-2" hwp:rel-id="ref-45">45</xref>]. Additionally, other HDAC1-3 inhibitors such as entinostat have been shown to reduce the production of pro-inflammatory cytokines IL-1 β and IL-6 in a rat collagen-induced arthritis model [<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref>] and inflammatory gene mRNA levels for IL-1β, IL-17, and IFN-γ in an experimental autoimmune neuritis rat model [<xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref>]. In this study we showed that Entinostat reduced intracellular IL-6 production but to a lower degree than SBHA, Panobinostat, and Pyroxamide and was therefore not studies further. However, it does strengthen the case that HDAC1-3 inhibition is a candidate pathway for inhibiting pro-inflammatory cytokines induced by PKC stimulation during HIV-1 latency reversal, as we demonstrated by combining known HDAC1-3 inhibitor SBHA with IDB to reduce the production of PKC-induced TNF-α, IL-17, and IL-5 ex vivo. While SBHA reduced PKC-induced pro-inflammatory cytokines, Panobinostat, a pan-HDAC inhibitor, did not significantly reduce pro-inflammatory cytokines. Panobinostat has been previously shown to significantly reduce IL-6 in a Hodgkin’s Lymphoma phase II clinical trial [<xref ref-type="bibr" rid="c46" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>] and IFN-γ secretion in a lymphocyte-target cell killing assay [<xref ref-type="bibr" rid="c47" hwp:id="xref-ref-47-1" hwp:rel-id="ref-47">47</xref>]. Other pan-HDACi such as TSA have been reported to reduce IL-6 [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-5" hwp:rel-id="ref-36">36</xref>] and TNF-α [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-6" hwp:rel-id="ref-36">36</xref>, <xref ref-type="bibr" rid="c48" hwp:id="xref-ref-48-1" hwp:rel-id="ref-48">48</xref>] secretion in LPS-stimulated macrophages, although other studies have shown that TSA has no effect on other pro-inflammatory genes such as IL-1β and IL-10 [<xref ref-type="bibr" rid="c48" hwp:id="xref-ref-48-2" hwp:rel-id="ref-48">48</xref>]. It is unclear why Panobinostat did not reduce PKC-induced pro-inflammatory cytokine production.</p><p hwp:id="p-31">The combination therapy of SBHA and IDB significantly reduced PKC-induced pro-inflammatory cytokines suggesting this combination therapy may be an effective strategy to decouple latency reversal and pro-inflammatory cytokine induction. Future experiments will examine the effect of one of our unexplored ‘hits’, Pyroxamide, on the production of PKC-induced pro-inflammatory cytokines.</p></sec><sec id="s5" hwp:id="sec-15"><label>5.</label><title hwp:id="title-21">Conclusions</title><p hwp:id="p-32">SBHA, a known HDAC1-3 inhibitor, substantially decreases Ingenol-3,20-dibenzoate-induced TNF-α, IL-2r, IL-5, and IL-17. These results suggest that IDB and SBHA may be a potential LRA combination therapy to reduce PKC-induced pro-inflammatory cytokines during latency reversal.</p></sec></body><back><ack hwp:id="ack-1"><title hwp:id="title-22">Acknowledgements</title><p hwp:id="p-33">The authors express their sincere gratitude to the study participants for their continued participation in this work and ongoing translational research. This work was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) grants AI122377-01 and AI143567-02 (VP), NIAID Ruth L. Kirschstein National Research Service Award T32AI055434-11 (ETL), NIAID grant R21AI124823-02 (LRB), and the Doris Duke Charitable Foundation Clinical Scientist Development Award CSDA201612 (AMS). The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002538. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></ack><sec id="s6" hwp:id="sec-16"><title hwp:id="title-23">Competing interests</title><p hwp:id="p-34">The authors declare no competing interests.</p></sec><sec id="s7" hwp:id="sec-17"><title hwp:id="title-24">Ethics approval</title><p hwp:id="p-35">Heathy donors and HIV-1 positive aviremic individuals on ART were recruited for phlebotomy according to Institutional Review Board (IRB) protocols 67637 (approved May 31, 2017) and 58246 (approved Jan 4, 2017) at the University of Utah.</p></sec><ref-list hwp:id="ref-list-1"><title hwp:id="title-25">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Gulick RM"><surname>Gulick</surname> <given-names>RM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mellors JW"><surname>Mellors</surname> <given-names>JW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Havlir D"><surname>Havlir</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Eron JJ"><surname>Eron</surname> <given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gonzalez C"><surname>Gonzalez</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="McMahon D"><surname>McMahon</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-2">Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy</article-title>. <source hwp:id="source-1">N Engl J Med</source>. <year>1997</year>;<volume>337</volume>(<issue>11</issue>):<fpage>734</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Hammer SM"><surname>Hammer</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Squires KE"><surname>Squires</surname> <given-names>KE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hughes MD"><surname>Hughes</surname> <given-names>MD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Grimes JM"><surname>Grimes</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Demeter LM"><surname>Demeter</surname> <given-names>LM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Currier JS"><surname>Currier</surname> <given-names>JS</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-3">A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team</article-title>. <source hwp:id="source-2">N Engl J Med</source>. <year>1997</year>;<volume>337</volume>(<issue>11</issue>):<fpage>725</fpage>–<lpage>33</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Perelson AS"><surname>Perelson</surname> <given-names>AS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Essunger P"><surname>Essunger</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cao Y"><surname>Cao</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vesanen M"><surname>Vesanen</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hurley A"><surname>Hurley</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Saksela K"><surname>Saksela</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-4">Decay characteristics of HIV-1-infected compartments during combination therapy</article-title>. <source hwp:id="source-3">Nature</source>. <year>1997</year>;<volume>387</volume>(<issue>6629</issue>):<fpage>188</fpage>–<lpage>91</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Chun TW"><surname>Chun</surname> <given-names>TW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stuyver L"><surname>Stuyver</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mizell SB"><surname>Mizell</surname> <given-names>SB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ehler LA"><surname>Ehler</surname> <given-names>LA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mican JA"><surname>Mican</surname> <given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Baseler M"><surname>Baseler</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-5">Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy</article-title>. <source hwp:id="source-4">Proceedings of the National Academy of Sciences</source>. <year>1997</year>;<volume>94</volume>(<issue>24</issue>):<fpage>13193</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5"><label>5.</label><citation publication-type="book" citation-type="book" ref:id="193946v2.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Finzi D"><surname>Finzi</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hermankova M"><surname>Hermankova</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pierson T"><surname>Pierson</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Carruth LM"><surname>Carruth</surname> <given-names>LM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Buck C"><surname>Buck</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chaisson RE"><surname>Chaisson</surname> <given-names>RE</given-names></string-name>, <etal>et al.</etal> <chapter-title>Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy</chapter-title>. <source hwp:id="source-5">Science</source> (<publisher-loc>New York, NY</publisher-loc>). <year>1997</year>;<volume>278</volume>(<issue>5341</issue>):<fpage>1295</fpage>–<lpage>300</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="book" citation-type="book" ref:id="193946v2.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Wong JK"><surname>Wong</surname> <given-names>JK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hezareh M"><surname>Hezareh</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Günthard HF"><surname>Günthard</surname> <given-names>HF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Havlir DV"><surname>Havlir</surname> <given-names>DV</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ignacio CC"><surname>Ignacio</surname> <given-names>CC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spina CA"><surname>Spina</surname> <given-names>CA</given-names></string-name>, <etal>et al.</etal> <chapter-title>Recovery of replication-competent HIV despite prolonged suppression of plasma viremia</chapter-title>. <source hwp:id="source-6">Science</source> (<publisher-loc>New York, NY</publisher-loc>). <year>1997</year>;<volume>278</volume>(<issue>5341</issue>):<fpage>1291</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="book" citation-type="book" ref:id="193946v2.7" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Torbett BE"><surname>Torbett</surname> <given-names>BE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Goodsell DS"><surname>Goodsell</surname> <given-names>DS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Richman DD"><surname>Richman</surname> <given-names>DD</given-names></string-name>, editors. <source hwp:id="source-7">The Future of HIV-1 Therapeutics-Resistance is Futile</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>; <year>2015</year>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Long L"><surname>Long</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fox M"><surname>Fox</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sanne I"><surname>Sanne</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosen S."><surname>Rosen</surname> <given-names>S.</given-names></string-name> <article-title hwp:id="article-title-6">The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa</article-title>. <source hwp:id="source-8">AIDS</source>. <year>2010</year>;<volume>24</volume>(<issue>6</issue>):<fpage>915</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Saberi P"><surname>Saberi</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Neilands TB"><surname>Neilands</surname> <given-names>TB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vittinghoff E"><surname>Vittinghoff</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Johnson MO"><surname>Johnson</surname> <given-names>MO</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chesney M"><surname>Chesney</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cohn SE"><surname>Cohn</surname> <given-names>SE</given-names></string-name>. <article-title hwp:id="article-title-7">Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants</article-title>. <source hwp:id="source-9">AIDS Patient Care STDS</source>. <year>2015</year>;<volume>29</volume>(<issue>3</issue>):<fpage>111</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Rintamaki LS"><surname>Rintamaki</surname> <given-names>LS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Davis TC"><surname>Davis</surname> <given-names>TC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Skripkauskas S"><surname>Skripkauskas</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bennett CL"><surname>Bennett</surname> <given-names>CL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wolf MS"><surname>Wolf</surname> <given-names>MS</given-names></string-name>. <article-title hwp:id="article-title-8">Social stigma concerns and HIV medication adherence</article-title>. <source hwp:id="source-10">AIDS Patient Care STDS</source>. <year>2006</year>;<volume>20</volume>(<issue>5</issue>):<fpage>359</fpage>–<lpage>68</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Katz IT"><surname>Katz</surname> <given-names>IT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ryu AE"><surname>Ryu</surname> <given-names>AE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Onuegbu AG"><surname>Onuegbu</surname> <given-names>AG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Psaros C"><surname>Psaros</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weiser SD"><surname>Weiser</surname> <given-names>SD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bangsberg DR"><surname>Bangsberg</surname> <given-names>DR</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-9">Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis</article-title>. <source hwp:id="source-11">J Int AIDS Soc</source>. <year>2013</year>;<volume>16</volume>(<issue>3 Suppl 2</issue>):<fpage>18640</fpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><collab hwp:id="collab-1">International ASSWGoHIVC</collab>, <string-name name-style="western" hwp:sortable="Deeks SG"><surname>Deeks</surname> <given-names>SG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Autran B"><surname>Autran</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Berkhout B"><surname>Berkhout</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Benkirane M"><surname>Benkirane</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cairns S"><surname>Cairns</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-10">Towards an HIV cure: a global scientific strategy</article-title>. <source hwp:id="source-12">Nat Rev Immunol</source>. <year>2012</year>;<volume>12</volume>(<issue>8</issue>):<fpage>607</fpage>–<lpage>14</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Borges AH"><surname>Borges</surname> <given-names>AH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dubrow R"><surname>Dubrow</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Silverberg MJ"><surname>Silverberg</surname> <given-names>MJ</given-names></string-name>. <article-title hwp:id="article-title-11">Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk</article-title>. <source hwp:id="source-13">Curr Opin HIV AIDS</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<fpage>34</fpage>–<lpage>40</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="High KP"><surname>High</surname> <given-names>KP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brennan-Ing M"><surname>Brennan-Ing</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Clifford DB"><surname>Clifford</surname> <given-names>DB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cohen MH"><surname>Cohen</surname> <given-names>MH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Currier J"><surname>Currier</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Deeks SG"><surname>Deeks</surname> <given-names>SG</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-12">HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group</article-title>. <source hwp:id="source-14">J Acquir Immune Defic Syndr</source>. <year>2012</year>;<volume>60</volume> <issue>Suppl 1</issue>:<fpage>S1</fpage>–<lpage>18</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Gopal S"><surname>Gopal</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Achenbach CJ"><surname>Achenbach</surname> <given-names>CJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yanik EL"><surname>Yanik</surname> <given-names>EL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dittmer DP"><surname>Dittmer</surname> <given-names>DP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Eron JJ"><surname>Eron</surname> <given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Engels EA"><surname>Engels</surname> <given-names>EA</given-names></string-name>. <article-title hwp:id="article-title-13">Moving forward in HIV-associated cancer</article-title>. <source hwp:id="source-15">J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>9</issue>):<fpage>876</fpage>–<lpage>80</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Elbirt D"><surname>Elbirt</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mahlab-Guri K"><surname>Mahlab-Guri</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bezalel-Rosenberg S"><surname>Bezalel-Rosenberg</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gill H"><surname>Gill</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Attali M"><surname>Attali</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Asher I."><surname>Asher</surname> <given-names>I.</given-names></string-name> <article-title hwp:id="article-title-14">HIV-associated neurocognitive disorders (HAND)</article-title>. <source hwp:id="source-16">Isr Med Assoc J</source>. <year>2015</year>;<volume>17</volume>(<issue>1</issue>):<fpage>54</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1 xref-ref-17-2"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Deeks SG"><surname>Deeks</surname> <given-names>SG</given-names></string-name>. <article-title hwp:id="article-title-15">HIV: Shock and kill</article-title>. <source hwp:id="source-17">Nature</source>. <year>2012</year>;<volume>487</volume>(<issue>7408</issue>):<fpage>439</fpage>–<lpage>40</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1 xref-ref-18-2"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Spivak AM"><surname>Spivak</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Planelles V."><surname>Planelles</surname> <given-names>V.</given-names></string-name> <article-title hwp:id="article-title-16">HIV-1 Eradication: Early Trials (and Tribulations)</article-title>. <source hwp:id="source-18">Trends Mol Med</source>. <year>2016</year>;<volume>22</volume>(<issue>1</issue>):<fpage>10</fpage>–<lpage>27</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Burton DR"><surname>Burton</surname> <given-names>DR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hangartner L."><surname>Hangartner</surname> <given-names>L.</given-names></string-name> <article-title hwp:id="article-title-17">Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design</article-title>. <source hwp:id="source-19">Annu Rev Immunol</source>. <year>2016</year>;<volume>34</volume>:<fpage>635</fpage>–<lpage>59</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Vandergeeten C"><surname>Vandergeeten</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fromentin R"><surname>Fromentin</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chomont N."><surname>Chomont</surname> <given-names>N.</given-names></string-name> <article-title hwp:id="article-title-18">The role of cytokines in the establishment, persistence and eradication of the HIV reservoir</article-title>. <source hwp:id="source-20">Cytokine Growth Factor Rev</source>. <year>2012</year>;<volume>23</volume>(<issue>4-5</issue>):<fpage>143</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Bartholomeeusen K"><surname>Bartholomeeusen</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xiang Y"><surname>Xiang</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fujinaga K"><surname>Fujinaga</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Peterlin BM"><surname>Peterlin</surname> <given-names>BM</given-names></string-name>. <article-title hwp:id="article-title-19">Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein</article-title>. <source hwp:id="source-21">J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>43</issue>):<fpage>36609</fpage>–<lpage>16</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.22" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Peng W"><surname>Peng</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hong Z"><surname>Hong</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chen X"><surname>Chen</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gao H"><surname>Gao</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dai Z"><surname>Dai</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhao J"><surname>Zhao</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-20">Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-kappaB Pathways Mediated by Heat Shock Response</article-title>. <source hwp:id="source-22">Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>(<issue>5</issue>).</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Chun TW"><surname>Chun</surname> <given-names>TW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Engel D"><surname>Engel</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mizell SB"><surname>Mizell</surname> <given-names>SB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ehler LA"><surname>Ehler</surname> <given-names>LA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fauci AS"><surname>Fauci</surname> <given-names>AS</given-names></string-name>. <article-title hwp:id="article-title-21">Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines</article-title>. <source hwp:id="source-23">J Exp Med</source>. <year>1998</year>;<volume>188</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>91</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Archin NM"><surname>Archin</surname> <given-names>NM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kirchherr JL"><surname>Kirchherr</surname> <given-names>JL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sung JA"><surname>Sung</surname> <given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Clutton G"><surname>Clutton</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sholtis K"><surname>Sholtis</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xu Y"><surname>Xu</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-22">Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency</article-title>. <source hwp:id="source-24">J Clin Invest</source>. <year>2017</year>;<volume>127</volume>(<issue>8</issue>):<fpage>3126</fpage>–<lpage>35</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.25" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Wu G"><surname>Wu</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Swanson M"><surname>Swanson</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Talla A"><surname>Talla</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Graham D"><surname>Graham</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Strizki J"><surname>Strizki</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gorman D"><surname>Gorman</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-23">HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal</article-title>. <source hwp:id="source-25">JCI Insight</source>. <year>2017</year>;<volume>2</volume>(<issue>16</issue>).</citation></ref><ref id="c26" hwp:id="ref-26"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Divsalar DN"><surname>Divsalar</surname> <given-names>DN</given-names></string-name>, <string-name name-style="western" hwp:sortable="Simoben CV"><surname>Simoben</surname> <given-names>CV</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schonhofer C"><surname>Schonhofer</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Richard K"><surname>Richard</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sippl W"><surname>Sippl</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ntie-Kang F"><surname>Ntie-Kang</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-24">Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening</article-title>. <source hwp:id="source-26">Front Pharmacol</source>. <year>2020</year>;<volume>11</volume>:<fpage>905</fpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Laird GM"><surname>Laird</surname> <given-names>GM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bullen CK"><surname>Bullen</surname> <given-names>CK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosenbloom DI"><surname>Rosenbloom</surname> <given-names>DI</given-names></string-name>, <string-name name-style="western" hwp:sortable="Martin AR"><surname>Martin</surname> <given-names>AR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hill AL"><surname>Hill</surname> <given-names>AL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Durand CM"><surname>Durand</surname> <given-names>CM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-25">Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations</article-title>. <source hwp:id="source-27">J Clin Invest</source>. <year>2015</year>;<volume>125</volume>(<issue>5</issue>):<fpage>1901</fpage>–<lpage>12</lpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1 xref-ref-28-2 xref-ref-28-3"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Spivak AM"><surname>Spivak</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bosque A"><surname>Bosque</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Balch AH"><surname>Balch</surname> <given-names>AH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Smyth D"><surname>Smyth</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Martins L"><surname>Martins</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Planelles V."><surname>Planelles</surname> <given-names>V.</given-names></string-name> <article-title hwp:id="article-title-26">Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients</article-title>. <source hwp:id="source-28">Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>10</issue>):<fpage>5984</fpage>–<lpage>91</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1 xref-ref-29-2"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Spina CA"><surname>Spina</surname> <given-names>CA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anderson J"><surname>Anderson</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Archin NM"><surname>Archin</surname> <given-names>NM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bosque A"><surname>Bosque</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chan J"><surname>Chan</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Famiglietti M"><surname>Famiglietti</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-27">An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients</article-title>. <source hwp:id="source-29">PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>(<issue>12</issue>):<fpage>e1003834</fpage>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1 xref-ref-30-2"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Darcis G"><surname>Darcis</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kula A"><surname>Kula</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bouchat S"><surname>Bouchat</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fujinaga K"><surname>Fujinaga</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Corazza F"><surname>Corazza</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ait-Ammar A"><surname>Ait-Ammar</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-28">An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression</article-title>. <source hwp:id="source-30">PLoS Pathog</source>. <year>2015</year>;<volume>11</volume>(<issue>7</issue>):<fpage>e1005063</fpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Genot EM"><surname>Genot</surname> <given-names>EM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Parker PJ"><surname>Parker</surname> <given-names>PJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cantrell DA"><surname>Cantrell</surname> <given-names>DA</given-names></string-name>. <article-title hwp:id="article-title-29">Analysis of the role of protein kinase C-alpha, -epsilon, and-zeta in T cell activation</article-title>. <source hwp:id="source-31">J Biol Chem</source>. <year>1995</year>;<volume>270</volume>(<issue>17</issue>):<fpage>9833</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1 xref-ref-32-2"><label>32.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Korin YD"><surname>Korin</surname> <given-names>YD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brooks DG"><surname>Brooks</surname> <given-names>DG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brown S"><surname>Brown</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Korotzer A"><surname>Korotzer</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zack JA"><surname>Zack</surname> <given-names>JA</given-names></string-name>. <article-title hwp:id="article-title-30">Effects of prostratin on T-cell activation and human immunodeficiency virus latency</article-title>. <source hwp:id="source-32">J Virol</source>. <year>2002</year>;<volume>76</volume>(<issue>16</issue>):<fpage>8118</fpage>–<lpage>23</lpage>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1 xref-ref-33-2 xref-ref-33-3 xref-ref-33-4"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Spivak AM"><surname>Spivak</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Larragoite ET"><surname>Larragoite</surname> <given-names>ET</given-names></string-name>, <string-name name-style="western" hwp:sortable="Coletti ML"><surname>Coletti</surname> <given-names>ML</given-names></string-name>, <string-name name-style="western" hwp:sortable="Macedo AB"><surname>Macedo</surname> <given-names>AB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Martins LJ"><surname>Martins</surname> <given-names>LJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bosque A"><surname>Bosque</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-31">Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo</article-title>. <source hwp:id="source-33">Retrovirology</source>. <year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>88</fpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1 xref-ref-34-2"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Martin AR"><surname>Martin</surname> <given-names>AR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pollack RA"><surname>Pollack</surname> <given-names>RA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Capoferri A"><surname>Capoferri</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ambinder RF"><surname>Ambinder</surname> <given-names>RF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Durand CM"><surname>Durand</surname> <given-names>CM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Siliciano RF"><surname>Siliciano</surname> <given-names>RF</given-names></string-name>. <article-title hwp:id="article-title-32">Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity</article-title>. <source hwp:id="source-34">J Clin Invest</source>. <year>2017</year>;<volume>127</volume>(<issue>2</issue>):<fpage>651</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1 xref-ref-35-2 xref-ref-35-3 xref-ref-35-4"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Reddy P"><surname>Reddy</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maeda Y"><surname>Maeda</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hotary K"><surname>Hotary</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu C"><surname>Liu</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Reznikov LL"><surname>Reznikov</surname> <given-names>LL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dinarello CA"><surname>Dinarello</surname> <given-names>CA</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-33">Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect</article-title>. <source hwp:id="source-35">Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>(<issue>11</issue>):<fpage>3921</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1 xref-ref-36-2 xref-ref-36-3 xref-ref-36-4 xref-ref-36-5 xref-ref-36-6"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Grabiec AM"><surname>Grabiec</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Krausz S"><surname>Krausz</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="de Jager W"><surname>de Jager</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Burakowski T"><surname>Burakowski</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Groot D"><surname>Groot</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sanders ME"><surname>Sanders</surname> <given-names>ME</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-34">Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue</article-title>. <source hwp:id="source-36">J Immunol</source>. <year>2010</year>;<volume>184</volume>(<issue>5</issue>):<fpage>2718</fpage>–<lpage>28</lpage>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1 xref-ref-37-2 xref-ref-37-3"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Leoni F"><surname>Leoni</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zaliani A"><surname>Zaliani</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bertolini G"><surname>Bertolini</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Porro G"><surname>Porro</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pagani P"><surname>Pagani</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pozzi P"><surname>Pozzi</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-35">The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines</article-title>. <source hwp:id="source-37">Proc Natl Acad Sci U S A</source>. <year>2002</year>;<volume>99</volume>(<issue>5</issue>):<fpage>2995</fpage>–<lpage>3000</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Perez M"><surname>Perez</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="de Vinuesa AG"><surname>de Vinuesa</surname> <given-names>AG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sanchez-Duffhues G"><surname>Sanchez-Duffhues</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Marquez N"><surname>Marquez</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bellido ML"><surname>Bellido</surname> <given-names>ML</given-names></string-name>, <string-name name-style="western" hwp:sortable="Munoz-Fernandez MA"><surname>Munoz-Fernandez</surname> <given-names>MA</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-36">Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency</article-title>. <source hwp:id="source-38">Curr HIV Res</source>. <year>2010</year>;<volume>8</volume>(<issue>6</issue>):<fpage>418</fpage>–<lpage>29</lpage>.</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Lu HK"><surname>Lu</surname> <given-names>HK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gray LR"><surname>Gray</surname> <given-names>LR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wightman F"><surname>Wightman</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ellenberg P"><surname>Ellenberg</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Khoury G"><surname>Khoury</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheng WJ"><surname>Cheng</surname> <given-names>WJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-37">Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy</article-title>. <source hwp:id="source-39">PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e113341</fpage>.</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Evelyn CR"><surname>Evelyn</surname> <given-names>CR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wade SM"><surname>Wade</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang Q"><surname>Wang</surname> <given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wu M"><surname>Wu</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Iniguez-Lluhi JA"><surname>Iniguez-Lluhi</surname> <given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Merajver SD"><surname>Merajver</surname> <given-names>SD</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-38">CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling</article-title>. <source hwp:id="source-40">Mol Cancer Ther</source>. <year>2007</year>;<volume>6</volume>(<issue>8</issue>):<fpage>2249</fpage>–<lpage>60</lpage>.</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Kulkosky J"><surname>Kulkosky</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Culnan DM"><surname>Culnan</surname> <given-names>DM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Roman J"><surname>Roman</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dornadula G"><surname>Dornadula</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schnell M"><surname>Schnell</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Boyd MR"><surname>Boyd</surname> <given-names>MR</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-39">Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART</article-title>. <source hwp:id="source-41">Blood</source>. <year>2001</year>;<volume>98</volume>(<issue>10</issue>):<fpage>3006</fpage>–<lpage>15</lpage>.</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1 xref-ref-42-2"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Durham BS"><surname>Durham</surname> <given-names>BS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Grigg R"><surname>Grigg</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wood IC"><surname>Wood</surname> <given-names>IC</given-names></string-name>. <article-title hwp:id="article-title-40">Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism</article-title>. <source hwp:id="source-42">J Neurochem</source>. <year>2017</year>;<volume>143</volume>(<issue>2</issue>):<fpage>214</fpage>–<lpage>24</lpage>.</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Lin HS"><surname>Lin</surname> <given-names>HS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hu CY"><surname>Hu</surname> <given-names>CY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chan HY"><surname>Chan</surname> <given-names>HY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liew YY"><surname>Liew</surname> <given-names>YY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huang HP"><surname>Huang</surname> <given-names>HP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lepescheux L"><surname>Lepescheux</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-41">Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents</article-title>. <source hwp:id="source-43">Br J Pharmacol</source>. <year>2007</year>;<volume>150</volume>(<issue>7</issue>):<fpage>862</fpage>–<lpage>72</lpage>.</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.44" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Zhang ZY"><surname>Zhang</surname> <given-names>ZY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang Z"><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schluesener HJ"><surname>Schluesener</surname> <given-names>HJ</given-names></string-name>. <article-title hwp:id="article-title-42">MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis</article-title>. <source hwp:id="source-44">Neuroscience</source>. <year>2010</year>;<volume>169</volume>(<issue>1</issue>):<fpage>370</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1 xref-ref-45-2"><label>45.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Ziesche E"><surname>Ziesche</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kettner-Buhrow D"><surname>Kettner-Buhrow</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weber A"><surname>Weber</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wittwer T"><surname>Wittwer</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jurida L"><surname>Jurida</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Soelch J"><surname>Soelch</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-43">The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-kappaB</article-title>. <source hwp:id="source-45">Nucleic Acids Res</source>. <year>2013</year>;<volume>41</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>109</lpage>.</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1"><label>46.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Oki Y"><surname>Oki</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Buglio D"><surname>Buglio</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang J"><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ying Y"><surname>Ying</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhou S"><surname>Zhou</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sureda A"><surname>Sureda</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-44">Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression</article-title>. <source hwp:id="source-46">Blood Cancer J</source>. <year>2014</year>;<volume>4</volume>:<fpage>e236</fpage>.</citation></ref><ref id="c47" hwp:id="ref-47" hwp:rev-id="xref-ref-47-1"><label>47.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="Klein JM"><surname>Klein</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Henke A"><surname>Henke</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sauer M"><surname>Sauer</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bessler M"><surname>Bessler</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Reiners KS"><surname>Reiners</surname> <given-names>KS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Engert A"><surname>Engert</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-45">The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines</article-title>. <source hwp:id="source-47">PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>11</issue>):<fpage>e79502</fpage>.</citation></ref><ref id="c48" hwp:id="ref-48" hwp:rev-id="xref-ref-48-1 xref-ref-48-2"><label>48.</label><citation publication-type="journal" citation-type="journal" ref:id="193946v2.48" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-48"><string-name name-style="western" hwp:sortable="Weiss U"><surname>Weiss</surname> <given-names>U</given-names></string-name>, <string-name name-style="western" hwp:sortable="Moller M"><surname>Moller</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Husseini SA"><surname>Husseini</surname> <given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Manderscheid C"><surname>Manderscheid</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hausler J"><surname>Hausler</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Geisslinger G"><surname>Geisslinger</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-46">Inhibition of HDAC Enzymes Contributes to Differential Expression of Pro-Inflammatory Proteins in the TLR-4 Signaling Cascade</article-title>. <source hwp:id="source-48">Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>23</issue>).</citation></ref></ref-list></back></article>
